0001209191-20-048263.txt : 20200825 0001209191-20-048263.hdr.sgml : 20200825 20200825171603 ACCESSION NUMBER: 0001209191-20-048263 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200824 FILED AS OF DATE: 20200825 DATE AS OF CHANGE: 20200825 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hoelscher Paul W. CENTRAL INDEX KEY: 0001611468 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 201133233 MAIL ADDRESS: STREET 1: 520 LAKE COOK ROAD, SUITE 520 STREET 2: C/O HORIZON PHARMA, INC. CITY: DEERFIELD STATE: IL ZIP: 60062 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 011-353-1-772-2100 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: Horizon Pharma plc DATE OF NAME CHANGE: 20140919 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-24 0 0001492426 Horizon Therapeutics Public Ltd Co HZNP 0001611468 Hoelscher Paul W. C/O HORIZON THERAPEUTICS PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4 IRELAND 0 1 0 0 EVP, CFO Ordinary Shares 2020-08-24 4 S 0 27753 75.73 D 104748 I By Trust Ordinary Shares 2020-08-24 4 S 0 1823 76.23 D 102925 I By Trust Ordinary Shares 1049 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2020. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.13 to $76.11 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.18 to $76.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes 1,049 ordinary shares of the Issuer acquired by the reporting person on June 1, 2020 pursuant to an employee stock purchase program. /s/ Miles W. McHugh, Attorney-in-Fact 2020-08-25